CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zhaoke Ophthalmology Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zhaoke Ophthalmology Ltd
No. 1 Meide 3rd Road, Pearl River
Industrial Park, Nansha District
Phone: +86 2039062888p:+86 2039062888 GUANGZHOU, GNG  China Ticker: 66226622
Business Summary
Zhaoke Ophthalmology Ltd is an investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs and products. The product pipelines primarily include NVK002 (Atropine) for myopia, CsA Ophthalmic Gel for DED and TAB014 (Bevacizumab) for wAMD. The products are primarily uses to treat eye diseases across both the front and the back of the eye, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), glaucoma and corneal epithelial dysfunction (CED). The Company conducts its business in the domestic market and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Chief Executive Officer XiaoyiLi 61 1/20/2017 1/20/2017
President, Chief Operating Officer, Chief Scientific Officer Lit FuiLau 59 1/28/2022 4/1/2019
Chief Financial Officer XinyanFeng 44 12/7/2020 12/7/2020
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 270 (As of 6/30/2025)
Outstanding Shares: 547,955,012 (As of 9/30/2025)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 17, 2025